Skip to main content

Table 3 Bivariate and multivariable analysis of CRPA cultures evaluating association between patient/facility characteristics and 90-day mortality

From: Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study

Characteristics
[n = 8204]
Death 90 days after culture date
(%) [N = 2012]
No death 90 days after culture date
(%) [N = 6192]
Unadjusted odds ratio
(95% CI)
Adjusted odds ratio
(95% CI)
Demographic and clinical characteristics     
 Male 1983 (98.6) 6019 (97.2) 1.97 (1.32–2.92)
Age category     
  18–49 36 (1.8) 354 (5.7) Reference Reference
  50–64 378 (18.8) 1516 (24.5) 2.45 (1.71–3.52) 1.83 (1.24–2.69)
  65 +  1598 (79.4) 4322 (69.8) 3.63 (2.57–5.14) 2.96 (2.04–4.29)
 Race     
  White 1514 (75.3) 4908 (79.3) Reference
  African American 469 (23.3) 1181 (19.1) 1.29 (1.15–1.45)
  Other* 29 (1.4) 103 (1.7) 0.91 (0.60–1.38)
 Ethnicity     
  Non-Latine 1799 (89.4) 5737 (92.7) Reference
  Latine 213 (10.6) 455 (7.3) 1.49 (1.26–1.77)
 Region     
  South 861 (42.8) 2533 (40.9) Reference Reference
  Midwest 370 (18.4) 1334 (21.5) 0.82 (0.71–0.94) 0.77 (0.66–0.90)
  West 391 (19.4) 1377 (22.2) 0.84 (0.73–0.96) 0.85 (0.73–0.99)
  Northeast 242 (12.0) 707 (11.4) 1.01 (0.95–1.19) 0.83 (0.69–1.00)
  U.S. Territory 148 (7.4) 241 (3.9) 1.81 (1.45–2.25) 1.23 (0.96–1.58)
 Rurality     
  Urban 1892 (94.0) 5733 (92.6) Reference
  Rural 120 (6.0) 459 (7.4) 0.79 (0.64–0.98)
 Facility complexity     
  High 1908 (94.8) 5578 (90.1) Reference
  Low 104 (5.2) 614 (9.9) 0.50 (0.40–0.61)
 Care setting     
  Outpatient 398 (19.8) 3117 (50.3) Reference Reference
  Long-term care 205 (10.2) 838 (13.5) 1.92 (01.59–2.31) 1.08 (0.86–1.36)
  Inpatient 1409 (70.0) 2237 (36.1) 4.93 (4.36–5.58) 2.95 (2.58–3.38)
 Specimen type     
  Urine 758 (37.7) 3565 (57.6) Reference Reference
  Respiratory 823 (40.9) 936 (15.1) 4.12 (3.66–4.56) 2.58 (2.25–2.96)
  Blood 91 (4.5) 93 (1.5) 4.60 (3.41–6.21) 2.82 (2.04–3.90)
  Other 340 (16.9) 1598 (25.8) 1.00 (0.87–1.15) 0.84 (0.72–0.98)
Co-morbidities     
 Mean Charlson Score (SD) 6 (3.1) 4 (2.9)  < 0.0001§ 1.13 (1.11–1.15)
 SCI/D     
  No 1813 (90.1) 5083 (82.1) Reference Reference
  Yes 199 (9.9) 1109 (17.9) 0.50 (0.43–0.59) 0.64 (0.53–0.77)
Antibiotic exposure in previous 90 days     
 Any antibiotics     
  No 1409 (70.0) 3445 (55.6) Reference Reference
  Yes 603 (30.0) 2747 (44.40 0.54 (0.48–0.60) 0.58 (0.52–0.66)
 Fluoroquinolones     
  No 1765 (87.7) 5098 (82.3) Reference
  Yes 247 (12.3) 1094 (17.7) 0.65 (0.56–0.76)
 3rd and 4th generation cephalosporins     
  No 1960 (97.4) 5971 (96.4) Reference
  Yes 52 (2.6) 221 (3.6) 0.72 (0.53–0.97)
 Carbapenems     
  No 1999 (99.4) 6163 (99.5) Reference
  Yes 13 (0.6) 29 (0.5) 1.38 (0.72–2.66)
 Length of stay 1 year prior to culture     
  Mean, median (SD) 73, 38 (92.1) 42, 10 (75.6)  < 0.0001§ 1.00 (1.00–1.00)
  1. Significant associations are shown in bold (p < 0.05)
  2. *Other includes, Asian, Native American and Pacific Islander
  3. Other specimen types include wounds, skin/soft tissue, body fluid, bone/joint, rectal cultures
  4. Respiratory specimen types include bronchial alveolar, tracheal aspirate, induced sputum, etc.
  5. §t-test p-value